The estimated Net Worth of Michael A Zasloff is at least $3.14 Milione dollars as of 5 March 2024. Mr. Zasloff owns over 12,500 units of Amphastar Pharmaceuticals Inc stock worth over $961,163 and over the last 10 years he sold AMPH stock worth over $1,883,970. In addition, he makes $292,007 as Independent Director at Amphastar Pharmaceuticals Inc.
Michael has made over 16 trades of the Amphastar Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 12,500 units of AMPH stock worth $589,750 on 5 March 2024.
The largest trade he's ever made was exercising 63,624 units of Amphastar Pharmaceuticals Inc stock on 2 October 2017 worth over $685,230. On average, Michael trades about 12,589 units every 129 days since 2014. As of 5 March 2024 he still owns at least 21,326 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Mr. Zasloff stock trades at the bottom of the page.
Michael A. Zasloff M.D. Ph.D. serves as Independent Director of the Company. Dr. Zasloff has served as our lead independent director since January 2016 and as a member of our board of directors since October 2005. Dr. Zasloff has been the Professor of Surgery and Pediatrics at the Georgetown University School of Medicine since 2002, and was also the Dean of Research and Translational Science from 2002 until 2004. Between 2004 and 2007, Dr. Zasloff served as Vice President and Senior Analyst (Life Sciences) at Ferris, Baker Watts, Inc., or FBW. From 1992 to 2001 Dr. Zasloff served as Executive Vice President and Vice Chairman of Magainin Pharmaceuticals Inc., a biopharmaceutical company which he founded. From 1988 until 1992, Dr. Zasloff served as the Charles E.H. Upham Professor in the Department of Pediatrics and Genetics at the University of Pennsylvania School of Medicine, and Chief, Division of Human Genetics and Molecular Biology at The Children’s Hospital of Philadelphia. From 1982 until 1988, Dr. Zasloff was Chief of the Human Genetics Branch at the National Institutes of Child Health and Human Development, National Institutes of Health. Dr. Zasloff received a B.A. from Columbia College in biochemistry and holds an M.D., Ph.D. from the New York University School of Medicine.
As the Independent Director of Amphastar Pharmaceuticals Inc, the total compensation of Michael Zasloff at Amphastar Pharmaceuticals Inc is $292,007. There are 13 executives at Amphastar Pharmaceuticals Inc getting paid more, with Jack Zhang having the highest compensation of $5,969,740.
Michael Zasloff is 74, he's been the Independent Director of Amphastar Pharmaceuticals Inc since 2019. There are 2 older and 13 younger executives at Amphastar Pharmaceuticals Inc. The oldest executive at Amphastar Pharmaceuticals Inc is Richard Koo, 79, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins e William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: